Pharmaceutical formulations of amyloid inhibiting compounds
View Patent ↗Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described.
1. An oral formulation comprising an effective amount of 3-amino-1-propanesulfonic acid to treat amyloidosis, inhibit amyloid deposition and/or treat an amyloid deposition-related disease, a pharmaceutically acceptable vehicle and an enteric coating, wherein the formulation results in lesser gastrointestinal intolerance in comparison to an immediate release dosage form comprising 3-amino-1-propanesulfonic acid.
2. An oral formulation comprising an effective amount of 3-amino-1-propanesulfonic acid, a pharmaceutically acceptable vehicle and an enteric coating,
wherein the formulation results in lesser gastrointestinal intolerance in comparison to an immediate release dosage form comprising 3-amino-1-propanesulfonic acid.
3. A formulation of claim 2 wherein the amount of 3-amino-1-propanesulfonic acid is effective for stabilizing cognitive function or decreasing the rate of decline in cognitive function.
4. A formulation of claim 2 wherein the amount of 3-amino-1-propanesulfonic acid is effective for inhibiting neurodegeneration or cellular toxicity induced by amyloid-β.
5. An oral formulation comprising 3-amino-1-propanesulfonic acid, a pharmaceutical acceptable carrier and an enteric coating wherein the formulation results in lesser gastrointestinal intolerance in comparison to an immediate release dosage form comprising 3-amino-1-propane sulfonic acid.
6. The formulation of claim 5 wherein 20% or less dissolution of 3-amino-1-propanesulfonic acid occurs in the acidic environment of the stomach but dissolution occurs in the more neutral or alkaline environments of the GI tract.
7. The formulation of claim 5 wherein less than or equal to 10% dissolution of the active ingredient occurs within 2 hours.
8. A method for stabilizing cognitive function or decreasing the rate of decline in cognitive function in a subject in need thereof comprising administering a formulation of claim 3 .
9. A method for inhibiting neurodegeneration or cellular toxicity induced by amyloid in a subject in need thereof comprising administering a formulation of claim 4 .
10. The method of claim 9 wherein said amyloid is amyloid-β.
11. A method for treating amyloidosis in a subject in need thereof comprising administering a formulation of claim 4 .
12. A method for inhibiting amyloid deposition in a subject in need thereof comprising administering a formulation of claim 4 .
13. A method for treating an amyloid-related diseases or conditions in a subject in need thereof comprising administering a formulation of claim 4 .
14. The method of claim 13 wherein said amyloid-related disease or condition is an amyloid-β-related disease or condition.
15. The method of claim 8 wherein said subject is an elderly individual.
16. The method of claim 14 wherein said amyloid-related disease or condition is selected from Alzheimer's disease, cerebral amyloid angiopathy, Down's syndrome, and mild cognitive impairment.
17. The method of claim 14 wherein said amyloid-related disease or condition is Alzheimer's disease or mild cognitive impairment.
18. A method for treating an amyloid-related disease in a human with brain amyloidosis comprising administering to the subject a therapeutic amount of a formulation of claim 3 , such that cognitive function is improved or stabilized or further deterioration in cognitive function is slowed.